RESEARCH ARTICLE OPEN ACCESS

A REVIEW ON SOLID DOSAGE FORMS DESIGN ASPECTS CONCEPTS

[1]Averineni Ravi Kumar, [2]K Narendra Kumar Reddy, [3]K Bhargav Bhushan Rao,[4]M Chinnaeswaraiah,[5]M B Venkatapathi Raju, [6]K. Atchuta Kumar,[7]K Rajesh

[1]Post Graduate Head of Department, Entrepreneurship Development Cell Cordinator, Nimra College of Pharmacy VIJAYAWADA 521456 AP INDIA
[2]Department of Pharmacy,Vikas Group of Institutions Nunna VIJAYAWADA 521212 AP INDIA
[3]Department of Pharmaceutics, A. M. Reddy Memorial College of Pharmacy Petluvaripalem NARASARAOPET 522601 AP INDIA
[4]Department of Pharmacognosy & Phytochemistry, Anurag College of Pharmacy, Anantagiri Road KODAD 508206 TG INDIA
[5]Department of Pharmaceutical Chemistry, Srinivasarao College of Pharmacy Pothinamallavapalem VISAKHAPATNAM 530041 AP INDIA
[6]Department of Pharmacognosy & Phytochemistry, Srinivasarao College of Pharmacy Pothinamallayapalem VISAKHAPATNAM 530041 AP INDIA
[7]Department of Pharmacology , Bhaskara Institute of Pharmacy , Komatipalli BOBBILI 535558 AP INDIA
***Corresponding Author**: karavi315@gmail.com

ABSTRACT

The development of solid dosage forms plays a vital role in pharmaceutical formulation, ensuring that medications are safe, effective, and acceptable to patients. Effective design involves careful consideration of various factors including the stability of the drug, its bioavailability, ease of manufacturing, and patient preferences. A thorough understanding of the active pharmaceutical ingredient's physical and chemical characteristics, combined with the appropriate choice of excipients and formulation methods, is key to achieving optimal drug release and therapeutic efficacy.In addition, ongoing advancements in pharmaceutical technology and formulation science are enhancing the ability to create more precise and tailored solid dosage forms. These innovations help overcome challenges such as controlled drug release, taste masking, and targeted delivery. In meticulous formulation design and comprehensive evaluation are fundamental to the successful development of solid dosage pharmaceutical products.

Keywords : Solid Dosage Forms , Evaluation Parameters , Challenges, Pharmaceuticals

INTRODUCTION

Oral solid dosage forms (OSDFs) are the most widely utilized systems for drug delivery, thanks to their ease of use, stability, patient compliance, and cost-effectiveness. The design of an effective OSDF requires collaboration across several disciplines, including pharmaceutical science, process engineering, regulatory affairs, and patient-focused design strategies. The following is a detailed overview of the OSDF development process.

◆ 1. Preformulation Studies

These studies form the groundwork of any formulation effort and are critical to ensuring the success of downstream processes.[1]

Preformulation Studies in Pharmaceutical Development

Preformulation studies serve as the groundwork for the development of any pharmaceutical product. These investigations are essential in understanding the **physical, chemical, and mechanical characteristics** of the **Active Pharmaceutical Ingredient (API)** and assessing how it interacts with potential **excipients**. The insights gained from preformulation guide formulation design, process development, and packaging strategy.



◆ Goals of Preformulation Studies

- To comprehensively evaluate the **API's properties**
- To detect and mitigate any **stability or compatibility challenges**
- To identify the most appropriate **excipients** and **manufacturing approaches**
- To ensure the **bioavailability**, **safety**, and **efficacy** of the final product
- To support **regulatory filings** with robust scientific data[2]

◆ 1. API Characterization



This involves studying the core properties of the drug substance.

A. Physical Characteristics

Property	Significance
Organoleptic traits	Attributes such as color, taste, and odor can influence patient compliance
Particle size & distribution	Affects drug solubility, uniformity, and processability
Crystal form/morphology	Impacts compressibility and flow
Bulk and tapped density	Important for calculating dosing volumes and designing packaging
Flowability (e.g., angle of repose, Carr's index, Hausner ratio)	Determines how easily powders can be processed
Hygroscopic behavior	Indicates moisture sensitivity, influencing storage and formulation
Polymorphism	Different crystalline forms may exhibit varied stability, solubility, and bioavailability

B. Chemical Characteristics

Property	Importance
Solubility (in water and solvents)	Influences dissolution and absorption profiles
pKa value	Determines the degree of ionization under physiological pH conditions
Partition coefficient (Log P)	Reflects the balance between lipophilicity and hydrophilicity; important for membrane permeability
Stability under stress	Assesses vulnerability to heat, light, moisture, and oxidation

◆ 2. Solubility Profiling

Understanding how the API dissolves in various media is crucial.

- **Intrinsic solubility**: Solubility of the drug in its unionized form, often in water.
- **pH solubility curve**: Determines solubility across a range of pH levels, mimicking conditions in the GI tract.
- **Solubility in organic solvents**: Helps with solvent selection for formulation or extraction processes.[3]

◆ 3. pKa and Ionization Analysis

- Helps predict how the drug ionizes in different environments.
- Affects **absorption**, **solubility**, and **formulation pH adjustment**.
- Guides buffer selection for improved stability and bioavailability.

◆ 4. Partition Coefficient (Log P)

- Measures the ratio of the drug's solubility in lipophilic (e.g., octanol) vs. aqueous (e.g., water) phases.[17]

- A crucial parameter for predicting **membrane permeability**.
- Ideal Log P values for oral absorption typically fall between **1 and 3**.



◆ **5. Polymorphic and Solid-State Analysis**

Polymorphism can significantly influence formulation performance.

Key differences among polymorphs:

- **Melting points**
- **Solubility and dissolution rates**
- **Physical stability**
- **Therapeutic performance[4]**

Analytical tools:

- **X-ray Powder Diffraction (XRPD)**
- **Differential Scanning Calorimetry (DSC)**
- **Thermogravimetric Analysis (TGA)**
- **FTIR spectroscopy**

◆ **6. Moisture Sorption (Hygroscopicity)**

- Determines how readily the drug absorbs moisture from its surroundings.
- Excess moisture uptake can lead to:
  - Decomposition
  - Clumping
  - Changes in flow behavior

Test Methods: Dynamic vapor sorption or controlled humidity exposure.[16]

◆ **7. Stability Testing (Stress Studies)**



Stability Testing Process Phase

Stress testing helps forecast long-term behavior under accelerated conditions.

Condition	Purpose
High temperature	Evaluates thermal degradation risk
Moisture exposure	Detects hydrolytic instability
Oxidizing conditions	Reveals sensitivity to oxygen or reactive agents
Light exposure	Identifies photodegradation tendencies

Used to define storage conditions and packaging needs.

◆ 8. Excipient Compatibility Studies

Establishes whether the API is chemically or physically reactive with common excipients.

Procedure:

- Mix the API with individual excipients (1:1 ratio typically)
- Store under accelerated conditions (e.g., 40°C/75% RH for 2–4 weeks)[15]
- Analyze using:
  - **DSC**
  - **FTIR**
  - **HPLC**

Outcomes:

- Identify any **color changes**, liquefaction, or degradation
- Guide **excipent selection** and formulation adjustments

◆ 9. Micromeritic Properties (Flow & Compression)

These are key for designing tablets and capsules.

Parameter	Purpose
Angle of repose	Measures powder flowability
Compressibility index (Carr's Index)	Indicates potential for compaction
Hausner ratio	Evaluates powder cohesiveness

Helps determine whether granulation or flow enhancers are needed.[5]

◆ 10. Other Relevant Evaluations

Property	Relevance
Compressibility	Determines ability to form hard, durable tablets
Lubricant sensitivity	Overuse may affect tablet disintegration and dissolution
Electrostatic properties	Can cause issues like sticking or poor mixing
Moisture content	Assessed via Karl Fischer titration or Loss on Drying (LOD) to evaluate stability risks



◆ Outcomes of Preformulation Studies

Parameter Evaluated	Impact on Drug Product Development
Solubility & pKa	Drives dissolution and absorption behavior
Stability (thermal, chemical)	Influences shelf-life and storage
Excipient Compatibility	Guides safe and effective excipient choices
Polymorphism	Affects consistency and performance
Powder Flow & Compression	Determines manufacturability and process flow
Particle Size Distribution	Influences content uniformity and release

A. Characterization of the Active Pharmaceutical Ingredient (API)

Characterizing an Active Pharmaceutical Ingredient (API) is an essential stage in the drug development lifecycle. It plays a crucial role in confirming the **identity, strength, quality, and stability** of the drug substance. Proper characterization ensures suitability for formulation development, compliance with regulatory standards, and consistent product quality throughout the drug's shelf life.[14]

1. Identity Confirmation

Objective: To verify the API's chemical identity and structural integrity.

Analytical Methods:

- **Infrared Spectroscopy (IR):** Identifies characteristic functional groups via vibrational transitions.
- **UV-Visible Spectroscopy (UV-Vis):** Detects conjugated systems and aromatic rings.
- **Mass Spectrometry (MS):** Provides molecular weight and structural fragmentation patterns.[13]
- **Nuclear Magnetic Resonance (NMR):**
  - **^{1}H NMR and ^{13}C NMR** confirm molecular structure.
- **X-ray Powder Diffraction (XRPD):** Differentiates crystalline forms and detects polymorphs.
- **Elemental Analysis (CHN):** Confirms empirical composition by measuring carbon, hydrogen, and nitrogen content.[6]

2. Purity Evaluation and Impurity Profiling

Objective: To determine the level of impurities and confirm compliance with purity standards.

Impurity Types:

- Organic (process/degradation-related)
- Inorganic (metal residues)
- Residual solvents (per ICH Q3C)
- Polymorphic variants
- Enantiomeric impurities (for chiral APIs)[12]

Analytical Techniques:

- **High-Performance Liquid Chromatography (HPLC)**
- **Gas Chromatography (GC)**
- **Thin-Layer Chromatography (TLC)**
- **Capillary Electrophoresis (CE)**
- **ICP-MS:** For heavy metals and elemental impurities.
- **Karl Fischer Titration:** Measures water content.



3. Assay (Potency Determination)

Objective: To accurately measure the concentration of API in a sample.

Methods:

- **HPLC or UPLC** with UV or MS detection
- **Titrimetric analysis** (where applicable)
- **UV-Vis Spectrophotometry**

4. Polymorphic and Crystalline Analysis[5]

Objective: To identify solid-state variations that may impact solubility, bioavailability, and stability.

Characterization Techniques:

- **XRPD:** Identifies crystalline patterns and polymorphs.
- **DSC (Differential Scanning Calorimetry):** Determines melting points and thermal transitions.[11]
- **TGA (Thermogravimetric Analysis):** Measures weight loss, such as solvent or water release.
- **Hot Stage Microscopy (HSM):** Visualizes thermal behavior under microscopy.

5. Hygroscopicity and Solubility Testing

Objective: To assess moisture uptake and solubility under various environmental conditions.

Tests Performed:

- **Dynamic Vapor Sorption (DVS):** Determines moisture absorption profiles.
- **Solubility Studies:** Conducted in water, buffer systems, and various solvents across pH ranges.[10]

6. Particle Size and Morphological Characterization

Objective: To evaluate particle size distribution and morphology, which influence dissolution and bioavailability.

Tools Used:

- **Laser Diffraction**
- **Dynamic Light Scattering (DLS)**
- **Microscopy (Optical, SEM):** For visualizing shape and surface texture.
- **BET Analysis:** Measures specific surface area.

7. Stability Analysis

Objective: To assess degradation pathways and estimate shelf life under various storage conditions.

Study Types:

- **Accelerated Testing:** e.g., 40°C ± 2°C / 75% RH ± 5%
- **Long-term Testing:** Per ICH guidelines.
- **Photostability Testing:** As per ICH Q1B.

Degradation Monitoring:

- **HPLC/UPLC**
- **LC-MS**
- **NMR**

8. Residual Solvent Analysis

Objective: To detect and quantify solvents used in manufacturing that may remain in the final API.[9]

Standard: ICH Q3C

Analytical Technique:[4]

- **Gas Chromatography (GC)** with flame ionization or mass detection.

9. Microbiological Testing (When Applicable)

Required for APIs used in sterile or sensitive dosage forms like injectables or ophthalmics.

Parameters:

- **Total Aerobic Microbial Count (TAMC)**
- **Total Yeast and Mold Count (TYMC)**
- **Pathogen Testing:** e.g., *Escherichia coli*, *Staphylococcus aureus*

10. Regulatory Compliance and Documentation

To meet global regulatory requirements, the following must be documented:[9]

- **Certificate of Analysis (CoA):** Includes identity, purity, potency, and other critical parameters.
- **ICH Guidelines:**
  - **Q3A:** Impurities in new drug substances
  - **Q3C:** Residual solvents
  - **Q6A:** Specifications
  - **Q1A/Q1B:** Stability testing

Table

Attribute	Techniques	Purpose
Identity	IR, NMR, MS, UV-Vis, XRPD	Confirm structure and composition
Purity/Impurities	HPLC, GC, CE, TLC, ICP-MS, KF	Detect and quantify impurities
Assay	HPLC, UV-Vis, Titration	Determine API concentration
Polymorphism	XRPD, DSC, TGA	Identify solid forms and transitions
Solubility	Shake Flask, DVS	Determine solubility and moisture uptake
Particle Size	Laser Diffraction, DLS, SEM	Analyze size and surface morphology
Residual Solvents	GC	Measure residual organic solvents
Stability	HPLC, LC-MS, NMR, DSC	Assess degradation and shelf life



Key properties examined include:

- **Solubility**, **pKa**, **partition coefficient (log P)**, and **hygroscopicity**

- **Polymorphic forms** and their effects on drug solubility and bioavailability
- **Particle size and morphology**, which affect flow characteristics and dissolution rate
- **Chemical and physical stability**, including resistance to thermal, oxidative, and hydrolytic degradation[3]

B. Compatibility Analysis

- Studying interactions between the API and potential excipients
- Identifying any undesirable solid-state or chemical reactions that could compromise stability or efficacy[8]

◆ 2. Dosage Form Selection

Several types of OSDFs are available, each selected based on therapeutic, physicochemical, and patient-specific criteria:

Common Types

- **Tablets**: including standard, coated, chewable, buccal, and sublingual forms
- **Capsules**: hard gelatin or soft gelatin varieties
- **Granules and powders**: either for direct consumption or reconstitution

Selection Considerations

- Drug **dose strength**
- API **stability**
- Desired **release characteristics** (e.g., immediate, sustained, controlled)
- Target **patient population** (e.g., pediatric, geriatric)

◆ 3. Formulation Development

Formulation Development involves the strategic design and optimization of a drug product by blending the **Active Pharmaceutical Ingredient (API)** with carefully selected **excipients**. This process results in a finished dosage form—such as tablets, capsules, creams, injections, or suspensions—that ensures the medicine is **safe, stable, effective**, and **acceptable** for patient use.[7]

1. Pre-formulation Studies

Objective:

To assess the fundamental **physicochemical** and **biopharmaceutical** attributes of the API, which guide formulation design.

Core Evaluations Include:

- **Solubility testing**: In various solvents (water, buffers, organic systems)
- **Ionization (pKa)**: Influences absorption and solubility
- **Log P (Partition Coefficient)**: Indicates lipid solubility
- **Stability studies**: Thermal, oxidative, and photostability assessments
- **Particle size and shape**: Affects drug dissolution and bioavailability

- **Hygroscopic nature**: Determines sensitivity to moisture
- **Excipients compatibility**: Ensures no adverse interactions during formulation



2. Choosing the Dosage Form

Deciding Factors:

- **Chemical characteristics** of the API
- **Intended route of administration** (oral, injectable, dermal, etc.)
- **Onset and duration of action** required (immediate, delayed, sustained)
- **Patient considerations**, such as age group or ease of administration[2]

Dosage Form Examples:

- **Solids**: Tablets, capsules, granules
- **Liquids**: Syrups, solutions, suspensions, emulsions
- **Semi-solids**: Creams, gels, ointments
- **Injectables**: Solutions, emulsions, lyophilized powders
- **Inhalables**: Aerosols, dry powders
- **Transdermal systems**: Patches, films

3. Selection of Excipients

Excipients are inactive components that support the formulation by improving stability, delivery, and usability.

Excipient Class	Function
Fillers/Diluents	Add volume to the formulation (e.g., lactose, MCC)
Binders	Promote particle adhesion in solid dosage forms
Disintegrants	Help tablets disintegrate after ingestion

Excipient Class	Function
Lubricants	Reduce friction during manufacturing
Glidants	Improve powder flow during processing
Preservatives	Inhibit microbial growth
Sweeteners/Flavors	Improve taste for better patient compliance
Release modifiers	Control the release rate of the drug
Solubilizers	Enhance dissolution and absorption of poorly soluble drugs
Buffers	Maintain pH of the final product

4. Formulation Trials and Optimization

What Happens Here:

Prototype formulations are developed, tested, and optimized using structured scientific approaches.

Methods Employed:

- **Design of Experiments (DoE)**: A statistical method to evaluate multiple variables efficiently
- **Quality by Design (QbD)**: Ensures formulation robustness through proactive planning
- **Batch Scaling**: Transitions from laboratory scale to pilot and production scale

Key Parameters for Optimization:

- Dissolution profile
- Drug content uniformity
- Tablet hardness and friability
- pH (for liquid dosage forms)
- Viscosity (for semi-solid systems)
- Drug release kinetics (especially in controlled-release products)

5. In-vitro Evaluation

Purpose:

To assess the formulation's **performance**, **quality**, and **consistency** before advancing to in-vivo or clinical studies.[1]

Common Laboratory Tests:

- **Dissolution testing**: Simulates how the drug dissolves in the body
- **Disintegration testing**: Measures how quickly tablets break down
- **Drug content uniformity**: Ensures even distribution of the API
- **Viscosity measurement**: Crucial for topical and liquid products
- **Particle size analysis**: Impacts absorption and stability
- **pH and osmolarity**: Important for injectables and ophthalmic preparations

6. Stability Studies

Objective:

To determine the product's **shelf life**, assess degradation, and establish proper **storage conditions**.[7]

Types of Stability Conditions (ICH Guidelines):

- **Long-term:** 25°C ± 2°C / 60% RH ± 5%
- **Accelerated:** 40°C ± 2°C / 75% RH ± 5%
- **Stress Testing:** Includes exposure to light, heat, humidity, and oxidative conditions

Parameters Monitored:

- Active ingredient potency
- Physical characteristics (color, appearance, odor)
- pH levels (especially in liquids)
- Microbiological stability (where applicable)
- Presence of degradation products

7. Bioavailability and Bioequivalence (BA/BE) Studies

Bioavailability (BA) and **Bioequivalence (BE)** studies are crucial components in drug development and regulatory approval, particularly for **generic formulations**. These studies are designed to assess how well a drug is absorbed into the body and whether two formulations deliver the same therapeutic effect.[2]



What Are BA/BE Studies?

- **Bioavailability (BA):** Refers to the **rate and extent** to which the active pharmaceutical ingredient (API) becomes available in systemic circulation following administration. It provides insights into how effectively the body can absorb the drug.
- **Bioequivalence (BE):** Involves the **comparison of two drug products** (typically a generic and a reference brand) to determine whether they deliver the **same amount of drug** into the bloodstream in a similar time frame.[3]



These studies are mandated by regulatory agencies such as the **FDA (USA)**, **EMA (Europe)**, **CDSCO (India)**, and **WHO** for the approval of both new and generic drug products.

1. Bioavailability (BA) Studies

Definition:

Bioavailability defines the **extent and speed** at which an active drug ingredient reaches systemic circulation and becomes available at its site of action.[4]

Types of Bioavailability:

Type	Description
Absolute Bioavailability	Compares the bioavailability of a non-intravenous dose (e.g., oral) to the same drug administered intravenously.
Relative Bioavailability	Compares different formulations (non-IV) of the same drug to assess performance.

Objectives of BA Studies:

- Characterize drug absorption behavior
- Guide formulation and dosage design
- Support adjustments in route or formulation
- Evaluate the effect of food on drug uptake[8]

Key Pharmacokinetic (PK) Parameters:

- **Cmax:** Maximum drug concentration in plasma
- **Tmax:** Time taken to reach Cmax
- **AUC (Area Under Curve):** Total drug exposure over time
- **t½ (Half-life):** Duration required for plasma concentration to reduce by 50%

2. Bioequivalence (BE) Studies

Definition:

BE studies determine whether two drug formulations (test vs. reference) are **therapeutically equivalent**, i.e., they provide comparable **rate and extent of absorption** under similar conditions.

When Are BE Studies Necessary?

- Generic drug approval (ANDA)
- Post-approval changes (manufacturing site, excipients)
- Dosage form modifications (e.g., tablet to capsule)
- Scale-up and post-approval production changes

3. Study Designs in BA/BE Research

Design Type	Description
Crossover Design	Each subject receives both test and reference products, separated by a washout period.
Parallel Design	Separate groups receive either test or reference formulations.
Replicate Design	Subjects receive multiple doses of each formulation to assess variability.

Important Considerations:

- Adequate **washout periods** to avoid carryover effects
- Typically **18–36 healthy adult volunteers**
- **Fasting vs. fed condition studies**
- **Controlled settings** for consistent results[5]

4. Pharmacokinetic Parameters Assessed

Parameter	Description	Significance
Cmax	Peak plasma concentration	Reflects absorption rate
Tmax	Time to reach Cmax	Indicates absorption speed
AUC_0–t	Area under plasma concentration curve to last time point	Measures drug exposure
AUC_0–∞	Total AUC extrapolated to infinity	Represents full systemic exposure
t½	Elimination half-life	Indicates drug elimination speed

5. Statistical Evaluation

- Data for **Cmax** and **AUC** are **log-transformed** for statistical comparison.
- **90% Confidence Intervals (CI)** are used.[9]
- **Acceptance Criteria:**
    - Regulatory agencies (e.g., FDA, EMA) require that the 90% CI for the **test/reference ratio** of Cmax and AUC fall within **80% to 125%**.
- **ANOVA (Analysis of Variance):** Applied to identify intra- and inter-subject variability.

6. Food Effect Studies

These studies assess whether **food impacts drug absorption**.

- Conducted under **fasted and fed** conditions
- Subjects receive a standardized **high-fat, high-calorie meal**
- Especially important for:
  - Drugs with a **narrow therapeutic index**
  - Formulations with **variable absorption patterns**

7. Ethical and Subject Considerations

- Volunteers are typically **healthy adults (18–55 years)**
- Ethical guidelines require:
  - **Informed consent**
  - **Approval by Ethics Committees or IRBs**
- Trials must follow **Good Clinical Practice (GCP)**

8. Documentation and Regulatory Submissions

Essential Documents:

- Study protocol
- Analytical method validation reports
- Individual and mean plasma concentration profiles
- Statistical data analysis
- Safety and adverse event reports

Submission Pathways:

- **FDA (USA):** Through ANDA or NDA
- **EMA (Europe):** Centralized or decentralized approval
- **CDSCO (India):** Form 45 or Form 46 applications
- **WHO PQP:** For global medicine procurement and listing[6]

9. In-vitro–In-vivo Correlation (IVIVC)

- **Definition:** A predictive mathematical model that relates **in-vitro drug release** to **in-vivo absorption data**.
- Commonly used for:
  - **Extended-release** or **modified-release** formulations
- Reduces need for repeated in-vivo trials

10. Biowaivers

Definition:

A **biowaiver** allows for **waiving in-vivo BE studies** under specific conditions.

Eligibility Criteria:

- API belongs to **BCS Class I or III** (high solubility and/or permeability)
- Product shows **rapid in-vitro dissolution**
- Intended for **immediate-release** oral dosage forms
- Complies with **ICH, FDA, EMA, or WHO guidelines**

Aspects of BA/BE Studies

Aspect	Details
Bioavailability	Measures absorption rate and extent
Bioequivalence	Confirms therapeutic equivalence of formulations
Study Designs	Crossover, parallel, replicate
Pharmacokinetic Metrics	Cmax, Tmax, AUC, t½
Statistical Criteria	80–125% acceptance range (90% CI for Cmax & AUC)
Special Studies	Food effect, IVIVC, multiple-dose
Ethical Compliance	GCP, informed consent, IRB approval
Regulatory Filing	CTD Module 5, BE reports, safety data

BA/BE studies are essential for confirming **drug performance, safety, and therapeutic equivalence**, particularly for **generic product approvals**. They support:

- Cost-effective healthcare through generic substitution
- Evidence-based regulatory decisions
- Patient access to **quality-assured medicines** globally[10]

Objective:

To confirm that the drug reaches systemic circulation in a predictable and reproducible manner.

Key Considerations:

- **Bioavailability studies** measure the rate and extent of drug absorption.
- **Bioequivalence studies** compare the test product (e.g., a generic) with an established reference product.
- **IVIVC (In-vitro In-vivo Correlation)**: Used to link lab-based tests with real-world absorption data, particularly for modified-release formulations.[1]

8. Scale-up and Technology Transfer

Goal:

To move from lab-scale production to **commercial manufacturing** while maintaining product quality and consistency.

Activities Involved:

- Validating manufacturing processes
- Selecting appropriate equipment
- Ensuring repeatable batch production

- Compliance with **Good Manufacturing Practices (GMP)**
- Preparing detailed documentation for transfer between R&D and manufacturing teams

9. Regulatory Submission and Documentation

All formulation work must be properly documented and submitted to **regulatory authorities** for drug approval

Required Documentation Includes:

- **Module 3.2.P** of the **Common Technical Document (CTD)**, which covers:
    - Composition and rationale
    - Manufacturing process
    - Control of critical quality attributes
- **Stability reports**
- **Bioavailability/Bioequivalence studies**
- **Justification of excipients**
- **Product development summary[2]**

Formulation Development Table

Stage	Objective	Tools & Tests Used
Pre-formulation	Evaluate API characteristics	Solubility, pKa, stability, compatibility
Dosage Form Selection	Choose optimal form for delivery	Based on route, API, patient needs
Excipient Selection	Ensure functionality and stability	Compatibility studies
Formulation Trials	Develop effective and reproducible formula	DoE, QbD, pilot batches
In-vitro Evaluation	Predict performance and quality	Dissolution, disintegration, uniformity

Stage	Objective	Tools & Tests Used
Stability Testing	Establish shelf life and degradation profile	ICH stability protocols
BA/BE Studies	Confirm in-vivo effectiveness	Pharmacokinetic and IVIVC studies
Scale-up & Tech Transfer	Prepare for large-scale production	Process validation, GMP compliance
Regulatory Documentation	Obtain approval for commercialization	CTD Module 3.2.P, development reports

This stage involves optimizing both the **qualitative and quantitative composition** of the dosage form.

A. Role of Excipients

Function	Common Examples
Diluent	Lactose, Microcrystalline Cellulose, Dicalcium Phosphate
Binder	Povidone (PVP), Hydroxypropyl Methylcellulose (HPMC), starch
Disintegrant	Croscarmellose Sodium, Sodium Starch Glycolate, Crospovidone
Lubricant	Magnesium Stearate, Stearic Acid
Glidant	Colloidal Silicon Dioxide, Talc
Coating Agents	HPMC, Polyethylene Glycol (PEG), Ethylcellulose
Flavoring/Coloring	FD&C dyes, menthol, vanilla

B. Designing the Drug Release Profile

- **Immediate-Release (IR)**: designed for rapid drug dissolution
- **Modified-Release (MR)** forms:
  - **Sustained-Release (SR)**
  - **Controlled-Release (CR)**
  - **Delayed-Release** (e.g., enteric-coated)[3]

◆ 4. Process Development and Manufacturing

Process Development Goals

The manufacturing method is chosen based on the drug and excipient properties:[11]

Tablet Manufacturing Techniques

Tablets are the most widely used solid dosage forms in the pharmaceutical sector, favored for their stability, ease of use, convenience in transport, and strong patient compliance. Tablet manufacturing involves transforming powders or granules containing the **active pharmaceutical ingredient (API)** and various excipients into compact solid units.



There are **three main approaches** to manufacturing tablets:

1. **Wet Granulation**
2. **Dry Granulation**
3. **Direct Compression[4]**

Each technique has specific applications based on the physical and chemical characteristics of the API and the formulation requirements.[12]

◆ 1. Wet Granulation Method

🔍 What It Is:

Wet granulation involves mixing the drug and excipients, followed by the addition of a liquid binder to create cohesive granules. This method enhances the powder's flow, compressibility, and blend uniformity.

Typical Process Steps:

1. **Weighing & Blending:**
   - The drug and excipients (fillers, binders, etc.) are accurately weighed and mixed.
2. **Granulation:**
   - A liquid (e.g., water, ethanol, or a binder solution) is added to convert the dry mixture into a moist mass.
3. **Wet Sieving:**
   - The moist mass is passed through a sieve to form granules of uniform size.
4. **Drying:**
   - The wet granules are dried using equipment such as a tray dryer or fluid bed dryer.
5. **Dry Milling:**
   - Dried granules are screened again to break down lumps and ensure consistency.
6. **Final Blending:**
   - Lubricants, glidants, and disintegrants are mixed into the dried granules.
7. **Compression:**
   - The final blend is compressed into tablets using a tablet press.

Advantages:

- Ideal for APIs with poor flow or compressibility.
- Ensures better dose uniformity.
- Reduces dust and improves handling.

⚠ Limitations:

- Involves more processing steps and higher costs.
- Not suitable for heat- or moisture-sensitive drugs.

◆ 2. Dry Granulation Method

🔍 What It Is:

This technique involves compressing the powder blend into compacts or ribbons **without using liquids**, making it suitable for APIs sensitive to moisture or heat.

Typical Process Steps:[5]

1. **Mixing:**
   - The drug and necessary excipients are dry blended.
2. **Compaction:**
   - The powder is compressed either by:
     - **Slugging**: Using a tablet press to form large slugs.
     - **Roller compaction**: Using rollers to produce ribbons.
3. **Size Reduction:**

- Slugs or ribbons are milled to form uniform granules.

4. **Final Blending:**
    - Lubricants and other agents are added to the granules.
5. **Tablet Compression:**
    - The granules are compressed into tablets.

Advantages:

- No exposure to heat or solvents—suitable for unstable APIs.
- Fewer processing stages compared to wet granulation.

Limitations:

- Requires APIs with good binding properties.
- May lead to inconsistent flow or blend uniformity if not optimized.

◆ 3. Direct Compression Method

What It Is:

In this method, the API and excipients are directly compressed into tablets **without any granulation step**, provided the formulation has adequate flow and compressibility.

Typical Process Steps:

1. **Initial Blending:**
    - The API is mixed with functional excipients such as diluents and disintegrants.
2. **Lubrication:**
    - Lubricants and glidants are incorporated.
3. **Compression:**
    - The final mixture is compressed directly into tablets.

Advantages:

- Simple, fast, and cost-efficient process.
- Ideal for heat- and moisture-sensitive materials.
- Fewer steps → lower contamination risk.[13]

Limitations:

- Limited to APIs with good flow and compressibility.
- Challenges with content uniformity in low-dose formulations.
- Risk of segregation due to differences in particle properties.[6]

Specialized Tablet Types & Technologies

Type of Tablet	Description
Effervescent Tablets	React with water to release CO_2, enhancing disintegration.

Type of Tablet	Description
ODTs (Orally Disintegrating Tablets)	Dissolve quickly in saliva for rapid onset.
Chewable Tablets	Intended to be chewed before swallowing.
Sublingual Tablets	Placed under the tongue for direct absorption into the bloodstream.
Modified-Release Tablets	Designed for sustained or delayed drug release.

Essential Equipment Used in Tablet Manufacturing

Stage	Equipment Example
Blending	V-blender, ribbon blender, double cone mixer
Wet Granulation	High-shear mixer, planetary granulator
Drying	Fluid bed dryer, tray dryer
Milling	Hammer mill, oscillating granulator
Compression	Rotary tablet press, single-punch tablet machine
Coating	Film coater, perforated pan coater

Quality Control Tests for Tablets

Test Name	Purpose
Hardness	Checks tablet strength during handling
Friability	Measures resistance to chipping or breaking
Weight Variation	Confirms uniform tablet weight
Disintegration	Evaluates how quickly the tablet breaks apart
Dissolution	Determines drug release rate in solution
Content Uniformity	Ensures consistent API dosage per tablet

Comparison of Tablet Manufacturing Methods

Feature	Wet Granulation	Dry Granulation	Direct Compression
Liquid Usage	Yes	No	No
Heat Exposure	Yes (during drying)	No	No
Best for	Poorly flowing powders	Heat/moisture-sensitive APIs	Compressible powders
Process Complexity	High	Moderate	Low
Cost of Equipment	High	Medium	Low
Degradation Risk	Higher	Low	Low

- **Direct Compression**: used for APIs with good flow and compressibility
- **Wet Granulation**: suitable for powders that are cohesive or poorly flowing
- **Dry Granulation**: ideal for moisture- or heat-sensitive drugs

Capsule Manufacturing



Capsules are one of the most widely used solid oral dosage forms in pharmaceuticals. They consist of one or more active pharmaceutical ingredients (APIs) and excipients enclosed within a soluble outer shell. Their popularity stems from their ease of swallowing, ability to mask unpleasant tastes and odors, and adaptability to different formulation types.[1]

There are **two main categories** of capsules based on their shell and content:

- **Hard Gelatin Capsules (HGCs)**
- **Soft Gelatin Capsules (SGCs)**

Each type follows a distinct manufacturing route, depending on the formulation requirements and the physical properties of the API.[14]

1. Hard Gelatin Capsules (HGCs)

Hard gelatin capsules are composed of two cylindrical pieces—a **cap** and a **body**—that fit together snugly. These shells are traditionally made from **gelatin** derived from animal collagen, although **vegetarian alternatives** like hydroxypropyl methylcellulose (HPMC) are now common.

HGCs are ideal for encapsulating powders, granules, pellets, and, in some cases, semi-solids or non-aqueous liquids.[15]

Manufacturing Process

A. Empty Capsule Shell Production ***(Performed by capsule shell manufacturers)***

1. **Gelatin Solution Preparation**
   Gelatin is dissolved in heated water along with plasticizers (e.g., glycerin or sorbitol) and optional colorants or opacifying agents.

2. **Dipping**
   Stainless steel pins shaped like capsule halves are dipped into the gelatin solution to form the capsule **body** and **cap**.
3. **Drying**
   The gelatin-coated pins are passed through controlled drying chambers to solidify the capsule shells.
4. **Stripping & Trimming**
   Once dried, shells are stripped off the pins and cut to a uniform size.
5. **Pre-Joining**
   The cap and body are lightly fitted together and sent to pharmaceutical manufacturers for filling.

B. Capsule Filling *(Performed by pharmaceutical manufacturers)*

1. **Formulation Preparation**
   The API is blended with excipients such as diluents, lubricants, glidants, and disintegrants to ensure flowability and content uniformity.
2. **Capsule Separation**
   Automated or manual systems separate the cap from the body.
3. **Filling**
   The capsule body is filled with:
   - Powders
   - Pellets
   - Granules
   - Mini-tablets
   - Non-aqueous liquids or semi-solids (requires sealing)[2]
4. **Rejoining (Locking)**
   The filled body and cap are locked together, forming a sealed unit.
5. **Polishing & Cleaning**
   Capsules are polished using soft brushes or polishing cloths to remove residual powder.

2. Soft Gelatin Capsules (SGCs)

Softgel capsules are **single-piece** shells made of gelatin, plasticizers, and water. They are filled with **liquids, suspensions**, or **semi-solids** and sealed during the formation process. Softgels are ideal for encapsulating oil-based formulations, fat-soluble drugs, or low-dose actives in solution.

Manufacturing Process

1. **Gelatin Mass Preparation**
   Gelatin is mixed with plasticizers (glycerin or sorbitol), purified water, and sometimes colorants or opacifiers.
2. **Fill Formulation Preparation**
   The API is dissolved or suspended in a suitable hydrophobic vehicle like oils, PEG, or waxes.
3. **Encapsulation (Rotary Die Process)**
   - Two gelatin ribbons are formed and fed into a **rotary die machine**.
   - Simultaneously, the fill material is injected between the ribbons.
   - Capsules are formed, sealed, shaped, and cut—all in one continuous step.
4. **Drying**
   Capsules are dried for 1–3 days under controlled conditions to achieve the correct hardness and moisture content.[16]

5. **Inspection & Packaging**
   After drying, defective units are removed, and acceptable capsules are packaged for storage or distribution.

Fill Materials Comparison

Capsule Type	Suitable Fill Materials
Hard Gelatin	Powders, pellets, granules, tablets, non-aqueous liquids
Soft Gelatin	Oils, emulsions, suspensions, waxy semi-solids

Key Equipment in Capsule Production

Process Stage	Equipment Used
Blending/Mixing	Ribbon blender, V-blender, high-shear mixer
Capsule Filling (HGCs)	Manual, semi-automatic, or automatic capsule fillers
Encapsulation (SGCs)	Rotary die encapsulation machine
Drying	Fluid bed dryer, tumble dryer
Polishing	Capsule polishing machine, cloth or soft brush systems
Visual Inspection	Manual inspection tables or automated vision systems[3]

Quality Control Tests for Capsules



Test	Purpose
Disintegration	Time taken for capsule to break down in test fluid
Dissolution	Measures the rate and extent of drug release
Weight Variation	Ensures uniformity in fill weight
Content Uniformity	Verifies consistent API distribution in dosage units

Test	Purpose
Moisture Content	Crucial for maintaining gelatin shell integrity
Microbial Limits	Ensures product is free of harmful microorganisms
Mechanical Strength	Evaluates capsule resistance to stress and handling

Comparison: Hard vs. Soft Gelatin Capsules[4]

Feature	Hard Gelatin Capsules	Soft Gelatin Capsules
Shell Design	Two-piece	One-piece
Fill Type	Solid or non-aqueous liquids	Liquids, suspensions, semi-solids
Manufacturing Complexity	Moderate	High
Moisture Content	~12–16%	~6–10%
Best For	Oral solids, modified release	Lipophilic drugs, oils
Storage Sensitivity	Less sensitive	Sensitive to heat and humidity

🌡 Storage & Packaging Considerations

- **Moisture Sensitivity**: Capsules must be stored in low-humidity environments.
- **Temperature Control**: Exposure to heat can cause deformation or melting.
- **Packaging Options**:
  - Blister packs with desiccants
  - HDPE containers
  - Strip packs[17]

Regulatory and Documentation Requirements

To ensure regulatory compliance and product safety, documentation and processes must align with global standards:

- **ICH Guidelines**:
  - Q1A: Stability Testing
  - Q6A: Specifications
- **GMP Compliance**:
  - Environment must meet cleanroom classification.
- **Essential Documents**:
  - Batch manufacturing records (BMR)
  - Equipment qualification reports
  - Cleaning and calibration logs
  - Certificate of Analysis (CoA)

- **Hard Gelatin Capsules**: typically filled with powders, granules, or pellets
- **Soft Gelatin Capsules**: suitable for encapsulating oils, suspensions, or semisolids

◆ 5. Coating of Solid Dosage Forms

Tablet coating serves multiple functions, including:

- Enhancing **appearance**
- **Masking taste** or odor
- **Protecting the drug** from moisture, light, or oxygen
- Enabling **modified or delayed drug release**

Types of Coating

- **Sugar Coating**: traditional but bulky
- **Film Coating**: thin polymeric films
- **Compression Coating**: used in complex release formulations

◆ 6. Evaluation and Quality Testing

Rigorous testing ensures that the dosage form meets pharmacopoeial and regulatory standards.

A. Physical and Mechanical Tests[5]

- **Weight variation**
- **Tablet hardness**
- **Friability**
- **Disintegration time**
- **Dissolution rate**

B. Chemical Testing

- **Active ingredient assay**
- **Uniformity of content**
- **Impurity/degradation analysis**

C. Stability Testing

- Carried out per ICH guidelines:[7]
  - **Accelerated conditions**: 40°C ± 2°C / 75% RH ± 5%
  - **Long-term conditions**: 25°C ± 2°C / 60% RH ± 5%

◆ 7. Packaging and Labeling

Packaging is selected to protect the product and enhance usability:

- Types include **blister packs**, **HDPE bottles**, and **strip packaging**
- Must ensure **barrier protection**, especially against light, moisture, and oxygen
- Design considerations for **child resistance** and **senior accessibility**

◆ 8. Regulatory and Compliance Factors

Formulations must comply with applicable regulations:

- **Good Manufacturing Practices (GMP)** adherence is essential
- Detailed **documentation** (batch records, master formulas) is required

- Regulatory filings may include:
  - **IND** (Investigational New Drug)
  - **ANDA** (Abbreviated New Drug Application)
  - **NDA** (New Drug Application)
- **Bioequivalence** studies are mandatory for generics

◆ 9. Patient-Centered Design

Designing for the end user is crucial for adherence and effectiveness:

- **Taste-masking** is important for pediatric use
- Tablet **size and shape** affect ease of swallowing
- **Clear labeling** improves correct usage
- **Scored tablets** allow flexible dosing

◆ 10. Innovations and Emerging Technologies

Recent advances in OSDFs include:

- **3D-printed tablets** for patient-specific therapies
- **Osmotic pump tablets** for precise, zero-order release
- **Multiparticulate systems** like mini-tablets or pellets within capsules
- **Fixed-dose combinations (FDCs)** for simplified regimens

◆ Table: OSDF Design Workflow

Stage	Core Focus
Preformulation	API properties, stability, compatibility
Dosage Form Selection	Dosage type based on drug/patient needs
Formulation Development	Excipients, release mechanisms
Manufacturing	Granulation, compression, encapsulation
Coating	Appearance, protection, release modification
Evaluation & Testing	Physical, chemical, dissolution, stability
Packaging	Moisture/light protection, usability
Regulatory Compliance	GMP, documentation, regulatory submissions
Patient-Centric Approach	Taste, swallowability, flexible dosing[6]

Solid dosage forms such as tablets and capsules must meet rigorous quality criteria to ensure patient safety, product efficacy, and consistent therapeutic outcomes. Quality control (QC) encompasses a range of physical, chemical, and microbiological evaluations, integral to pharmaceutical manufacturing.[8]

1. Physical Quality Control Tests

1.1 Appearance and Visual Inspection

Objective: Detect physical defects including chips, cracks, discoloration, or contamination.
Method: Visual examination performed manually or by automated systems under adequate lighting.
Acceptance: Dosage units must be free from visible imperfections, with consistent color, shape, and size according to specifications.[1]

1.2 Weight Variation Test

Objective: Confirm uniformity in individual unit weights to guarantee dose accuracy.
Method:

- Randomly select 20 units.
- Individually weigh each using a calibrated balance.
- Calculate the average weight and determine each unit's deviation.
  Acceptance Limits:
- Tablets ≤80 mg: ±10%
- Tablets 80–250 mg: ±7.5%
- Tablets >250 mg: ±5%

1.3 Thickness and Size Measurement

Objective: Ensure consistent tablet thickness and size for packaging and dose uniformity.
Method: Use Vernier calipers or micrometers to measure a sample batch's thickness and diameter (for round tablets).[9]
Acceptance: Values should fall within ±5% of the mean size.

1.4 Hardness (Crushing Strength) Test

Objective: Assess the mechanical strength of tablets to withstand handling and packaging processes.
Method: Using tablet hardness testers (e.g., Monsanto, Pfizer models), measure the force required to break tablets.[10]
Acceptance: Typical hardness ranges from 4 to 8 kg/cm², depending on formulation.

1.5 Friability Test

Objective: Evaluate the resistance of tablets to abrasion and mechanical shocks.
Method:

- Weigh ~20 tablets.
- Subject them to 100 revolutions in a friabilator at 25 rpm.
- Dedust and reweigh tablets.
- Calculate percentage weight loss.
  Acceptance: Weight loss should not exceed 1%.

1.6 Disintegration Test

Objective: Measure the time required for tablets or capsules to break down into smaller particles suitable for dissolution.
Method: Employ USP disintegration apparatus with a basket-rack assembly, using water or simulated gastric fluid at 37°C ±2°C.

Acceptance: Immediate-release tablets typically disintegrate within 15 minutes unless specified otherwise.[2]

2. Chemical Quality Control Tests

2.1 Assay of Active Pharmaceutical Ingredient (API)

Objective: Quantify the precise amount of API to ensure proper dosage.
Method: Extract the drug from the dosage form using a suitable solvent, followed by analysis through validated techniques such as HPLC, UV-Vis spectrophotometry, or titration.
Acceptance: The API content should typically be within 90–110% of the labeled amount, subject to pharmacopeial guidelines.[11]

2.2 Content Uniformity Test

Objective: Ensure consistent API distribution among individual dosage units.
Method:

- Randomly select 10 units.
- Perform individual API assays.
- Calculate mean and relative standard deviation (RSD).
  Acceptance: Each unit should contain 85–115% of the labeled API content with an acceptable RSD.

2.3 Dissolution Test

Objective: Evaluate the rate and extent of drug release from the dosage form under standardized conditions.[12]
Method:

- Use USP dissolution apparatus (Type I basket or Type II paddle).
- Employ appropriate dissolution media, temperature, and agitation speed.
- Collect samples at predetermined intervals and analyze API concentration.
  Acceptance: Results should comply with pharmacopeial or product-specific release criteria.[3]

2.4 Identification Test

Objective: Confirm the presence of the correct API in the dosage form.
Method: Techniques include infrared (IR) spectroscopy, thin-layer chromatography (TLC), or HPLC, comparing sample results with a reference standard.
Acceptance: The test results should match the reference standard's characteristics.

3. Microbiological Quality Control Tests

3.1 Microbial Limit Tests

Objective: Ensure the product is free from harmful microbial contamination.
Method:

- Determine total aerobic microbial count and total yeast and mold count.

- Screen specifically for pathogens such as *E. coli*, *Salmonella*, and *Staphylococcus aureus*. **Acceptance:** Counts must comply with established pharmacopeial limits.

3.2 Sterility Test (For Sterile Solid Dosage Forms)

Objective: Confirm sterility of dosage forms intended to be sterile, e.g., implants.
Method: Incubate samples in culture media and observe for microbial growth.
Acceptance: No microbial growth is detected during the incubation period.[4]

4. Other Essential Quality Tests

4.1 Moisture Content

Objective: Control moisture levels, which can affect product stability, microbial growth, and mechanical properties.[13]
Method: Analyze using Karl Fischer titration, loss on drying, or moisture analyzers.
Acceptance: Moisture must be within formulation-specific limits.

4.2 Uniformity of Dosage Units

This test integrates weight variation and content uniformity to confirm that each dosage unit delivers the intended amount of API consistently.

5. Regulatory Compliance and Documentation

- Quality testing aligns with standards outlined in pharmacopeias such as USP, BP, EP, and JP.
- Compliance with ICH guidelines (especially Q6A for specifications and Q1A for stability) is mandatory.
- All tests must adhere to Good Manufacturing Practices (GMP).
- Thorough documentation, including batch records, validation protocols, and certificates of analysis, is essential for batch release and regulatory audits.

6. Summary Table of Key Quality Tests for Solid Dosage Forms

Test Name	Purpose	Typical Acceptance Criteria
Appearance Inspection	Detect visual defects	No cracks, discoloration, or contamination
Weight Variation	Ensure uniform mass	±5–10% depending on tablet weight
Thickness/Size	Maintain consistent dimensions	±5% variation from average
Hardness	Assess mechanical strength	4–8 kg/cm² (formulation-dependent)
Friability	Measure resistance to abrasion	≤1% weight loss
Disintegration	Measure break down time	≤15 minutes for immediate release
Assay	Quantify API content	90–110% of label claim
Content Uniformity	Verify API consistency	85–115% with acceptable RSD
Dissolution	Test drug release profile	Meets pharmacopeial/product-specific standards

Test Name	Purpose	Typical Acceptance Criteria
Identification	Confirm API identity	Matches reference standard
Microbial Limits	Confirm microbial safety	Within pharmacopeial limits
Moisture Content	Control moisture level	Within formulation-specified limits[5]

Advanced Dosage Form Design



Dosage form design involves the process of transforming an active pharmaceutical ingredient into a final medicinal product that can be administered safely and effectively to patients. Advanced dosage form design goes beyond traditional tablets and capsules by employing innovative delivery systems that optimize drug targeting, enhance therapeutic efficacy, improve patient adherence, and reduce adverse effects.[14]

Goals of Advanced Dosage Form Design

- **Targeted Delivery:** Directing the medication to specific tissues or organs to maximize therapeutic effects while minimizing systemic exposure.
- **Controlled or Modified Release:** Regulating the release profile of the drug to maintain therapeutic levels over a desired time frame and at specific locations.
- **Enhanced Bioavailability:** Improving the absorption and stability of drugs that are poorly soluble or prone to degradation.

- **Better Patient Compliance:** Developing formulations that are easier to use, require less frequent dosing, or have improved taste and convenience.
- **Reduced Side Effects:** Limiting toxicity by localizing drug action or controlling systemic distribution.
- **Protection of the Drug:** Safeguarding sensitive drugs from breakdown by environmental factors such as stomach acid or enzymes.
- **Combination Therapies:** Facilitating simultaneous or sequential delivery of multiple drugs in one formulation.[6]

Categories of Advanced Dosage Forms

1. **Sustained and Controlled Release Systems**
   Aim to keep drug levels steady in the bloodstream over extended periods. Examples include matrix tablets, reservoir devices, and osmotic pump systems. Benefits include fewer doses and improved treatment adherence.
2. **Targeted Drug Delivery Systems (TDDS)**
   Designed to deliver drugs precisely to the desired site. This can be passive, relying on natural distribution mechanisms (e.g., nanoparticle accumulation in tumors), or active, using ligands or antibodies that bind to specific cellular receptors. Examples are liposomes, antibody-drug conjugates, and nanoparticles.[15]
3. **Transdermal Systems**
   Facilitate drug delivery through the skin, offering the advantage of bypassing first-pass metabolism and enabling controlled drug release. Common examples include nicotine and hormone patches.
4. **Colonic Delivery Systems**
   Formulated to release drugs specifically in the colon, which is useful for treating local diseases like inflammatory bowel disease or for delivering drugs unstable in the upper gastrointestinal tract.[1]
5. **Microspheres and Nanoparticles**
   These tiny carriers improve drug solubility, stability, and targeting, and are employed in cancer therapies, vaccines, and gene delivery.
6. **Multiparticulate Systems**
   Comprised of small units like pellets or granules that can be coated for varying release rates within one dosage form.
7. **Osmotic Systems**
   Use osmotic pressure to provide a steady and controlled drug release, typically unaffected by pH changes or food intake.
8. **Mucoadhesive Systems**
   Designed to stick to mucosal membranes (oral, nasal, vaginal) for localized or systemic drug absorption.[2]

Important Factors in Designing Advanced Dosage Forms

- **Physicochemical Drug Characteristics:** Including solubility, stability, pKa, molecular size, and permeability, which influence the selection of formulation strategies.[16]
- **Pharmacokinetic and Pharmacodynamic Profiles:** Drug half-life, metabolism, site of absorption, and therapeutic window help guide release timing and targeting.
- **Route of Administration:** Different routes (oral, transdermal, injectable, nasal, ocular) present unique formulation challenges and opportunities.

- **Patient Considerations:** Factors such as age, health condition, and likelihood of adherence impact design decisions.
- **Manufacturing Feasibility:** Availability of production technologies, scalability, and cost constraints must be considered.
- **Regulatory and Safety Requirements:** Compatibility of excipients, toxicity concerns, and quality assurance are essential for approval and safe use.

Examples of Advanced Dosage Forms with Commercial Products

Dosage Form	Description	Example Products
Liposomes	Drug encapsulated in phospholipid vesicles	Doxil (doxorubicin)
Nanoparticles	Submicron-sized drug carriers	Abraxane (paclitaxel)
Osmotic Pumps	Controlled release via osmotic pressure	Glucotrol XL (glipizide)
Transdermal Patches	Adhesive patches for skin delivery	Nicotine and fentanyl patches
Buccal/Sublingual Films	Thin films that dissolve in the mouth	Nitroglycerin
Injectable Depot Systems	Long-acting injectable formulations	Risperdal Consta (risperidone)

Emerging Trends in Dosage Form Design[3]

- Personalized medicine with drug delivery tailored to individual patient needs.
- Development of smart delivery systems that respond to biological signals like pH, temperature, or enzymes.
- Use of 3D printing technology for customizable dosage forms and release profiles.
- Advanced delivery vehicles for gene and cell therapies.[17]

CONCLUSION

Advances in Solid Dosage Form Design

◆ 1. Controlled and Modified Drug Release Systems

- **Extended-, Delayed-, and Pulsatile-Release Dosage Forms**
  These systems are designed to release medication at a controlled rate, after a specific delay, or in pulses to match circadian rhythms or specific therapeutic needs.
  Examples include matrix-based tablets, osmotic pump systems like **OROS®**, and formulations with enteric coatings.[7]

◆ 2. Targeted Drug Delivery Systems

- **Gastrointestinal Site-Specific Delivery**
  These formulations ensure the drug is released at a particular site in the gastrointestinal tract, such as the colon.
  This is achieved using **pH-dependent polymers** or **enzyme-responsive delivery systems**.

Nanotechnology-Based Formulations

a. Nanoformulations

- Reducing drug particle size to the nano scale improves **solubility**, **dissolution rate**, and **absorption**, especially for poorly soluble drugs (BCS Class II and IV).
- Preparation techniques include **wet milling**, **nano-spray drying**, and **supercritical fluid processing**.[8]

b. Solid Lipid Nanoparticles (SLNs) & Nanocrystals

- These nanostructured systems offer enhanced **stability**, **bioavailability**, and **controlled drug release** profiles.

3D Printing in Pharmaceuticals

- **Customized Drug Products**
  3D printing allows for precise customization of dosage forms in terms of dose, shape, and release characteristics.
  Technologies: Fused Deposition Modeling (FDM), Selective Laser Sintering (SLS), and Inkjet Printing.[9]
  Example: **Spritam® (levetiracetam)** – the first FDA-approved medicine manufactured using 3D printing.

Advanced Solid-State Chemistry

a. Pharmaceutical Co-Crystals

- Combine active pharmaceutical ingredients with co-formers to enhance **solubility**, **stability**, and **bioavailability** without altering the drug's molecular structure.[10]

b. Amorphous Solid Dispersions (ASDs)

- Convert crystalline drugs to amorphous forms to improve dissolution.
- Commonly stabilized using polymers like **HPMC** or **PVP**.

Innovations in Manufacturing

a. Continuous Manufacturing

- An integrated production process that offers **higher efficiency**, **real-time quality monitoring**, and **reduced production costs**.[11]

b. Hot-Melt Extrusion (HME)

- Used for producing solid dispersions and sustained-release formulations.
- Benefits include **solubility enhancement**, **taste masking**, and **solvent-free processing**.

Multi-Unit Pellet Systems (MUPS)

- These systems consist of drug-loaded pellets compressed into tablets or encapsulated.
- They provide **flexible drug release**, reduce **gastric irritation**, and improve **dose uniformity**.[12]
  Example: **Losec MUPS® (omeprazole)**.

a Patient-Centered Formulation Design

a. Orally Disintegrating Tablets (ODTs)

- Designed to dissolve quickly in the mouth without water, improving convenience for children and elderly patients.[13]
  Example: **Zofran ODT**.

b. Mini-Tablets & Multiparticulate Systems

- Offer **dose flexibility** and **ease of swallowing**, especially suitable for pediatric use.

Advanced Coating Techniques

- Coatings enhance **taste masking**, **site-specific release**, and **controlled drug delivery**.
- Technologies like **electrostatic spray coating** and **fluidized bed coating** improve precision and efficiency.[14]

Modeling, Simulation, and Quality by Design

- Implementing **QbD (Quality by Design)** and **PAT (Process Analytical Technology)** tools enables better **formulation optimization**, **process control**, and **regulatory compliance**.[15]

Eco-Friendly and Sustainable Practices

- Focus on using **green excipients**, **solvent-free manufacturing methods** (e.g., HME), and **biodegradable packaging materials** to minimize environmental impact.

Table of Key Advances

Focus Area	Recent Advancement
Drug Release	Controlled, delayed, pulsatile systems
Bioavailability Enhancement	Nanotech-based delivery, co-crystals, ASDs
Personalization	3D printing for patient-specific doses
Manufacturing	Continuous production, HME
Pediatric/Geriatric Formulation	ODTs, mini-tablets, multiparticulates
Targeted Delivery	Site-specific systems (pH/enzyme-triggered)
Regulation & Quality	QbD frameworks, PAT integration
Sustainability	Green excipients, solvent-free processes

The future of designing solid dosage forms lies in personalized treatments, improved drug delivery systems, and increased patient adherence.[4] Cutting-edge technologies like 3D printing allow for the creation of tailored medications that meet individual patient needs. Progress in nanotechnology and the use of smart polymers offer enhanced precision in controlling drug release and targeting specific sites in the body. [16]Furthermore, advances in formulation techniques are improving taste masking, accelerating disintegration, and enhancing the stability of medications.[5] The incorporation of digital health technologies alongside solid dosage forms is set to transform how medication adherence is tracked and managed. [17]In summary, upcoming innovations will focus on making solid dosage forms more efficient, user-friendly, and suitable for complex therapeutic challenges.[6]

AKNOWLEDGEMENTS : The authors are thankful to all in preparing this article and apply for International Patent in “Bioadhesive and Floating Tablet Formulation of Herbal Antidiabetic Agents using Natural Gums.”

REFERENCES

[1]Ansel, H.C., Popovich, N.G., & Allen, L.V. (2018). *Pharmaceutical Dosage Forms and Drug Delivery Systems* (10th ed.). Lippincott Williams & Wilkins.

[2]Lachman, L., Lieberman, H.A., & Kanig, J.L. (1986). *The Theory and Practice of Industrial Pharmacy* (3rd ed.). Varghese Publishing.

[3]Aulton, M.E. (2017). *Aulton’s Pharmaceutics: The Design and Manufacture of Medicines* (5th ed.). Elsevier.

[4]Remington: The Science and Practice of Pharmacy (2020). 25th Edition. Pharmaceutical Press.

[5]Shargel, L., Wu-Pong, S., & Yu, A.B.C. (2012). *Applied Biopharmaceutics & Pharmacokinetics* (6th ed.). McGraw-Hill Education.

[6]Iqbal, M., et al. (2020). Recent developments in oral solid dosage formulations: formulation approaches, characterization techniques, and in vitro-in vivo correlations. *Drug Development and Industrial Pharmacy*, 46(6), 871–886.

[7] Aulton, M. E., & Taylor, K. M. G. (2017).
Aulton's Pharmaceutics: The Design and Manufacture of Medicines (5th ed.). Elsevier Health Sciences.

[8]Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (2009).*Handbook of Pharmaceutical Excipients* (6th ed.). Pharmaceutical Press..

[9]Bhakay, A., et al. (2018).*International Journal of Pharmaceutics, 548*(1), 140–152. https://doi.org/10.1016/j.ijpharm.2018.06.030

[10]Löbmann, K., & Grohganz, H. (2022)..*Pharmaceutics, 14*(1), 1–22.https://doi.org/10.3390/pharmaceutics14010001

[11]Awad, A., et al. (2021)..*International Journal of Pharmaceutics, 601*, 120372. https://doi.org/10.1016/j.ijpharm.2021.120372

[12]Kalepu, S., & Nekkanti, V. (2015).*Acta Pharmaceutica Sinica B, 5*(5), 442–453. https://doi.org/10.1016/j.apsb.2015.07.003

[13]Verma, R. K., & Garg, S. (2001).*Pharmaceutical Technology, 25*(2), 1–14.

[14]Wen, H., & Park, K. (Eds.). (2011). *Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice*. Wiley.

[15]European Medicines Agency (EMA). https://www.ema.europa.eu

[16]U.S. Food and Drug Administration (FDA) https://www.fda.gov

[17]Patra, C. N., et al. (2017). *Journal of Controlled Release*, *25*(6), 81–90. https://doi.org/10.1016/j.jconrel.2017.03.002

